RBC Cuts Price Target on Adverum Biotechnologies to $15 From $20, Maintains Sector Perform, Speculative Risk
Adverum Biotechnologies Analyst Ratings
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation
Truist Securities: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $60.00.
Adverum Biotechnologies Analyst Ratings
Adverum Biotechnologies Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
Adverum Biotechnologies (ADVM.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $30.00.
Adverum Biotechnologies Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Adverum Biotechnologies With Buy Rating, Announces Price Target of $30
Mizuho Bank: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $40.00 to $22.00.
Adverum Biotechnologies Analyst Ratings
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Analyst Ratings
Chardan Capital Reiterates Buy on Adverum Biotechnologies, Maintains $4 Price Target
Adverum Biotechnologies Analyst Ratings
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk
Adverum Biotechnologies (ADVM) Initiated With a Hold at RBC Capital
Adverum Biotechnologies (ADVM) Receives a Buy From TD Cowen
Adverum Biotechnologies Analyst Ratings